RT Journal Article
SR Electronic
T1 Metabolic signature of the ganglion cell–inner plexiform layer thickness and the risks of mortality and morbidity: a population-based study in UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.26.22280334
DO 10.1101/2022.09.26.22280334
A1 Yang, Shaopeng
A1 Yuan, Yixiong
A1 Chen, Yanping
A1 Zhang, Shiran
A1 Wang, Yujie
A1 Shang, Xianwen
A1 Bulloch, Gabriella
A1 Liao, Huan
A1 Chen, Yifan
A1 Zhang, Lei
A1 Zhu, Zhuoting
A1 He, Mingguang
A1 Wang, Wei
YR 2022
UL http://medrxiv.org/content/early/2022/09/26/2022.09.26.22280334.abstract
AB Background The retina is considered a unique window to systemic health, but their biological link remains unknown.Methods A total of 93,838 UK Biobank participants with metabolomics data were included in the study. Plasma metabolites associated with GCIPLT were identified in 7,824 participants who also underwent retinal optical coherence tomography; prospective associations of GCIPLT-associated metabolites with 12-year risk of mortality and major age-related diseases were assessed in 86,014 participants. The primary outcomes included all- and specific-cause mortality. The secondary outcomes included incident type 2 diabetes mellitus (T2DM), obstructive sleep apnea/hypopnea syndrome (OSAHS), myocardial infarction (MI), heart failure, ischemic stroke, and dementia. C-statistics and net reclassification indexes (NRIs) were calculated to evaluate the added predictive value of GCIPLT metabolites. Calibration was assessed using calibration plots.Findings Sixteen metabolomic signatures were associated with GCIPLT (P< 0.009 [Bonferroni-corrected threshold]), and most were associated with the future risk of mortality and age-related diseases. The constructed meta-GCIPLT scores distinguished well between patients with high and low risks of mortality and morbidity, showing predictive values higher than or comparable to those of traditional risk factors (C-statistics: 0.780[0.771-0.788], T2DM; 0.725[0.707-0.743], OSAHS; 0.711[0.695-0.726], MI; 0.685[0.662-0.707], cardiovascular mortality; 0.657[0.640-0.674], heart failure; 0.638[0.636-0.660], other mortality; 0.630[0.618-0.642], all-cause mortality; 0.620[0.598-0.643], dementia; 0.614[0.593-0.634], stroke; and 0.601[0.585-0.617], cancer mortality). The NRIs confirmed the inclusion of GCIPLT metabolomic signatures to the models based on traditional risk factors resulted in significant improvements in model performance (5.18%, T2DM [P=3.86E-11]; 4.43%, dementia [P=0.003]; 4.20%, cardiovascular mortality [P=6.04E-04]; 3.73%, MI [P=1.72E-07]; 2.93%, OSAHS [P=3.13E-05]; 2.39%, all-cause mortality [P=3.89E-05]; 2.33%, stroke [P=0.049]; 2.09%, cancer mortality [P=0.039]; and 1.59%, heart failure [P=2.72E-083.07E-04]). Calibration plots showed excellent calibration between predicted risk and actual incidence in the new models.Interpretation GCIPLT-associated plasma metabolites captured the residual risk for mortality and major systemic diseases not quantified by traditional risk factors in the general population. Incorporating GCIPLT metabolomic signatures into prediction models may assist in screening for future risks of these health outcomes.Funding National Natural Science Foundation (China).Evidence before this study Recent studies have recognized that retinal measurements can indicate an accelerated risk of aging and multiple systemic diseases preceding clinical symptoms and signs. Despite these insights, it remains unknown how retinal alterations are biologically linked to systemic health.Added value of this study Using the UK Biobank, we identified ganglion cell–inner plexiform layer thickness (GCIPLT) metabolomic signatures, and revealed their association with the risk of all- and specific-cause mortality and six age related diseases: type 2 diabetes, dementia, stroke, myocardial infarction, heart failure, and obstructive sleep apnea/hypopnea syndrome. The meta-GCIPLT score significantly improved the discriminative power of the predictive models for theses health outcomes based on conventional risk factors.Implications of all the available evidence GCIPLT-associated plasma metabolites have the potential to capture the residual risk of systemic diseases and mortality not quantified by traditional risk factors. Incorporating GCIPLT metabolomic signatures into prediction models may assist in screening for future risks of these health outcomes. Since metabolism is a modifiable risk factor that can be treated medically, the future holds promise for the development of new strategies that reverse or interrupt the onset of these diseases by modifying metabolic factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Natural Science Foundation of China (82000901), the Guangzhou Science & Technology Plan of Guangdong Pearl River Talents Program (202102010162), the Fundamental Research Funds of the State Key Laboratory of Ophthalmology (303060202400362).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used (or will use) ONLY openly available human data from UK Biobank via data access procedures (http://www.ukbiobank.ac.uk). Permission to use the UK Biobank Resource was obtained via material transfer agreement as part of Application 62443, 62489, 62491 and 62525. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.OCToptical coherence tomographyGCIPLganglion cell-inner plexiform layerRNFLretinal nerve fiber layerGCIPLTGCIPL thicknessRGCretinal ganglion cellOSAHSobstructive sleep apnea/hypopnea syndromeMImyocardial infarctionNHSNational Health ServiceNMRnuclear magnetic resonanceBMIbody mass indexWHRwaist-to-hip ratioIOPintraocular pressureCIconfidence intervalHDLhigh-density lipoproteinapoEapolipoprotein EapoA1apolipoprotein A1FAfatty acid,SEstandard errorapoBapolipoproteinB; TGtriglycerideVLDLvery low-density lipoproteinIHintermittent hypoxiaAβamyloid β